Biotech InnovationOrbiMed-incubated startup Pinnacle Medicines is pioneering a novel class of oral peptide therapeutics designed to match the effectiveness of biologics typically administered via injection. With a lead program targeting respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD), this funding round situates Pinnacle to enter clinical stages and potentially transform treatment paradigms by enhancing patient compliance and convenience.
Jonathan Blake·Apr 6, 2026
AI in Drug DiscoveryIndustry experts suggest that the future leaders in healthcare AI will be distinguished by their ability to embed their technology within existing medical environments, leverage unique data assets, and effectively navigate commercialization challenges. This analysis delves into the key factors that could determine winners and losers in the evolving healthcare AI landscape.
Jonathan Blake·Apr 5, 2026 
Regulatory & PolicyThe Centers for Medicare & Medicaid Services (CMS) has recently decided to scale back the number of performance measures it employs to rate health insurers, particularly affecting Medicare Advantage plans. This decision has led to a significant financial windfall for these plans, with estimates indicating an $18.6 billion increase. This development has sparked discussion and analysis regarding regulatory approaches and the implications for health insurer accountability.
Jonathan Blake·Apr 3, 2026 
Regulatory & PolicyEndometriosis presents significant diagnostic and therapeutic challenges, and ACOG’s new guidelines aim to improve patient care by standardizing approaches and integrating latest research findings. Dr. Barbara Levy discusses key updates and implications for clinicians and patients.
Jonathan Blake·Apr 2, 2026 
Biopharmaceutical IndustryDespite significant workforce reductions at Novo Nordisk’s former Catalent manufacturing site, there are clear indicators of recovery and renewed commitment to the facility. Scholar Rock’s recent inclusion of the site in its FDA approval resubmission underscores these investments. This article explores the complex dynamics between operational challenges and strategic investments at this pivotal location.
Jonathan Blake·Apr 1, 2026 
Regulatory & PolicyRobert Malone’s resignation from the vaccine committee has drawn attention to the internal dynamics between health committee members and government spokespersons. Malone cited his unwillingness to engage in drama as a key reason for stepping down, following public comments and disputes involving the Department of Health and Human Services.
Jonathan Blake·Mar 27, 2026 
Biopharmaceutical IndustrySeeking to bolster its pipeline with innovative cancer treatments, Merck has announced its intent to acquire Terns Pharmaceuticals for $6.7 billion. This deal prioritizes a promising leukemia drug candidate, aiming to enhance treatment options for patients affected by this challenging disease.
Jonathan Blake·Mar 25, 2026 
Biopharmaceutical IndustryThe pharmaceutical industry is undergoing significant shifts in research and development spending. In 2025, the top 16 largest companies spent a total of $159 billion on R&D, marking a 3.6% decrease from $165 billion the previous year. This change reflects evolving priorities and strategic decisions about which programs to advance amidst a competitive and financially challenging environment.
Jonathan Blake·Mar 25, 2026 
Regulatory & PolicyThe FDA's recent admonishment of prominent biotech figures over unsubstantiated claims highlights ongoing issues in maintaining scientific integrity and protecting patients. This article examines the regulatory intervention's background and broader implications for biotech communications.
Jonathan Blake·Mar 24, 2026 
Regulatory & PolicyThe drug price controls in Japan present complexities that complicate access, innovation, and international relations. Both Washington and Tokyo face obstacles that call for cooperative approaches to regulatory and economic reforms.
Jonathan Blake·Mar 24, 2026 
Regulatory & PolicyRecent FDA findings highlight the emergence of seizure incidents associated with Parkinson’s drugs containing carbidopa/levodopa. The agency has reported cases linked to vitamin B6 deficiency, underscoring the need for heightened awareness among healthcare providers and patients alike.
Jonathan Blake·Mar 23, 2026 
Medical TechnologyThe COVID-19 pandemic's early impact in the U.S. was far more severe than initially recorded. This study reveals dramatic disparities in death counts and points to systemic challenges in early viral surveillance and reporting. Understanding these discrepancies is crucial for public health policy and future pandemic response.
Jonathan Blake·Mar 18, 2026 